# Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)

> **NCT01138124** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 54202 (actual)

## Conditions studied

- Renal Pelvis Cancer
- Restless Legs Syndrome
- Epilepsy
- Neuropathic Pain
- Chronic Pancreatitis
- Hypertension
- Pancreatic Cancer
- Diabetes
- Renal Cancer
- Renal Cell Carcinoma

## Interventions

- **DRUG:** Gabapentin prescriptions

## Key facts

- **NCT ID:** NCT01138124
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 54202 (ACTUAL)
- **Last updated:** 2017-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01138124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01138124, "Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01138124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*